Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

(2017) Dmitriy Zamarin et al.   Nature Communications

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

(2017) Zuqiang Liu et al.   Nature Communications

Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation

(2017) So Young Kim et al.   Oncotarget

Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy

(2016) Weizhou Hou et al.   CANCER CELL

Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells

(2016) A Takasu et al.   CANCER GENE THERAPY

The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model

(2016) Xiaozhu Li et al.   CLINICAL CANCER RESEARCH

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy

(2016) E Ilett et al.   GENE THERAPY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

ΔPK oncolytic activity includes modulation of the tumour cell milieu

(2016) Dominique Bollino et al.   JOURNAL OF GENERAL VIROLOGY

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells

(2016) Mehmet Okyay Kilinc et al.   Journal of Translational Medicine

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers

(2016) Stephanie Downs-Canner et al.   MOLECULAR THERAPY

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

(2016) Karishma Rajani et al.   MOLECULAR THERAPY

Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses

(2016) Amber Miller et al.   MOLECULAR THERAPY

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

(2016) Anne M Noonan et al.   MOLECULAR THERAPY

Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+T cells

(2016) Ravikumar Muthuswamy et al.   PROSTATE

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

The oncolytic peptide LTX-315 triggers immunogenic cell death

(2016) H Zhou et al.   Cell Death & Disease

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer

(2016) Lily Francis et al.   Oncotarget

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

(2016) Tania Løve Aaes et al.   Cell Reports

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

(2016) Patricia Kleinpeter et al.   OncoImmunology

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia

(2015) W. Shen et al.   BLOOD

IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses

(2015) Xuefeng Wang et al.   CANCER CELL

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection

(2015) Rozanne Arulanandam et al.   CANCER CELL

TGF  Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response

(2015) J. Han et al.   CANCER RESEARCH

The Impact of Macrophage- and Microglia-Secreted TNF  on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment

(2015) W. H. Meisen et al.   CLINICAL CANCER RESEARCH

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy

(2015) J. J. Rojas et al.   CLINICAL CANCER RESEARCH

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques

(2015) Laura Evgin et al.   MOLECULAR THERAPY

Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses

(2015) Norman Woller et al.   MOLECULAR THERAPY

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

(2015) Herbert J Zeh et al.   MOLECULAR THERAPY

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

(2015) Carolina S Ilkow et al.   NATURE MEDICINE

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Immune checkpoint modulation: Rational design of combination strategies

(2015) Dmitriy Zamarin et al.   PHARMACOLOGY & THERAPEUTICS

Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

(2015) José I. Quetglas et al.   Cancer Immunology Research

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy

(2015) Zuqiang Liu et al.   OncoImmunology

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

(2015) Ilkka Liikanen et al.   OncoImmunology

Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency

(2015) Olga V Matveeva et al.   Molecular Therapy-Oncolytics

Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

(2015) Ravikumar Muthuswamy et al.   Journal for ImmunoTherapy of Cancer

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

(2015) Georgina V Long et al.   Journal for ImmunoTherapy of Cancer

Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells

(2014) Ke Jiang et al.   BMC CANCER

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers

(2014) T Du et al.   CANCER GENE THERAPY

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

(2014) N. Nishio et al.   CANCER RESEARCH

Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

(2014) Y. Mao et al.   CLINICAL CANCER RESEARCH

Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death

(2014) Carolien A. Koks et al.   INTERNATIONAL JOURNAL OF CANCER

Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer

(2014) Svend O. Freytag et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

(2014) Fiona Errington et al.   JOURNAL OF IMMUNOLOGY

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently

(2014) Justin W. Ady et al.   SURGERY

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy

(2014) Irena Adkins et al.   OncoImmunology

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

(2014) Andrew Zloza et al.   Journal for ImmunoTherapy of Cancer

Oncolytic Viruses as Anticancer Vaccines

(2014) Norman Woller et al.   Frontiers in Oncology

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity

(2014) Zong Sheng Guo et al.   Frontiers in Oncology

Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses

(2014) Nicole E. Forbes et al.   Frontiers in Oncology

Inhibitors of C5 complement enhance vaccinia virus oncolysis

(2013) D Magge et al.   CANCER GENE THERAPY

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

(2013) C. J. Breitbach et al.   CANCER RESEARCH

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

(2013) H Inoue et al.   CELL DEATH AND DIFFERENTIATION

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Oncolytic viruses as therapeutic cancer vaccines

(2013) David L Bartlett et al.   Molecular Cancer

Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy

(2013) Samuel T Workenhe et al.   MOLECULAR THERAPY

T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy

(2013) Feng Yu et al.   MOLECULAR THERAPY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy

(2013) S. T. Workenhe et al.   Cancer Immunology Research

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines

(2013) Byram W Bridle et al.   OncoImmunology

Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

(2012) L. B. John et al.   CANCER RESEARCH

Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

(2012) S. Pesonen et al.   CANCER RESEARCH

Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

(2012) S. Miyamoto et al.   CANCER RESEARCH

NF- B Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

(2012) R. Muthuswamy et al.   CANCER RESEARCH

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

(2012) E. M. Karapanagiotou et al.   CLINICAL CANCER RESEARCH

Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation

(2012) B Thaci et al.   GENE THERAPY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Viral subversion of immunogenic cell death

(2011) Oliver Kepp et al.   CELL CYCLE

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

(2011) J D Dias et al.   GENE THERAPY

Measles virus causes immunogenic cell death in human melanoma

(2011) O G Donnelly et al.   GENE THERAPY

Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus

(2011) Phonphimon Wongthida et al.   HUMAN GENE THERAPY

Vesicular Stomatitis Virus Expressing Tumor Suppressor p53 Is a Highly Attenuated, Potent Oncolytic Agent

(2011) J. F. Heiber et al.   JOURNAL OF VIROLOGY

Oncolytic Herpes Simplex Virus 1 Encoding 15-Prostaglandin Dehydrogenase Mitigates Immune Suppression and Reduces Ectopic Primary and Metastatic Breast Cancer in Mice

(2011) J. D. Walker et al.   JOURNAL OF VIROLOGY

Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer

(2011) Jun Li et al.   MOLECULAR THERAPY

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

(2011) B. Diop-Frimpong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

(2010) Vincenzo Cerullo et al.   CANCER RESEARCH

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

(2010) E. Galanis et al.   CANCER RESEARCH

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

Impact of tumor microenvironment on oncolytic viral therapy

(2010) Jeffrey Wojton et al.   CYTOKINE & GROWTH FACTOR REVIEWS

TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer

(2010) M F Ziauddin et al.   GENE THERAPY

Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma

(2010) B. Boozari et al.   GUT

Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver

(2010) Sunil K. Geevarghese et al.   HUMAN GENE THERAPY

Enhancement of NK cell antitumor responses using an oncolytic parvovirus

(2010) Rauf Bhat et al.   INTERNATIONAL JOURNAL OF CANCER

Potentiating Cancer Immunotherapy Using an Oncolytic Virus

(2010) Byram W Bridle et al.   MOLECULAR THERAPY

Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth

(2010) Sonia Guedan et al.   MOLECULAR THERAPY

Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy

(2010) Paul T Sobol et al.   MOLECULAR THERAPY

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand

(2009) H. S. Kim et al.   CANCER RESEARCH

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma

(2009) F Galivo et al.   GENE THERAPY

The HSV-2 mutant ΔPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins

(2009) A G Colunga et al.   GENE THERAPY

The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

(2009) Robin J. Prestwich et al.   HUMAN GENE THERAPY

Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity

(2009) Natalia Lapteva et al.   JOURNAL OF IMMUNOTHERAPY

Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus

(2009) Byram W Bridle et al.   MOLECULAR THERAPY

Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity

(2009) Jeanette E Boudreau et al.   MOLECULAR THERAPY

Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response

(2008) A. Gauvrit et al.   CANCER RESEARCH

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

(2008) R. J. Prestwich et al.   CLINICAL CANCER RESEARCH

Immunogenic cancer cell death: a key-lock paradigm

(2008) Antoine Tesniere et al.   CURRENT OPINION IN IMMUNOLOGY

Oncolytic viruses: a novel form of immunotherapy

(2008) Robin J Prestwich et al.   Expert Review of Anticancer Therapy

Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy

(2008) Adam Vigil et al.   MOLECULAR THERAPY

The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma

(2008) Ta-Chiang Liu et al.   MOLECULAR THERAPY

Regulation of maturation and activating potential in CD8+ versus CD8− dendritic cells following in vivo infection with vaccinia virus

(2008) Rama D. Yammani et al.   VIROLOGY